ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26 th International AIDS Conference ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced today that it will make three ...

Disruptions to funding and new policies aimed at aligning foreign aid programs with the Trump administration’s agenda have ...

Around 77,000 fewer children worldwide received HIV treatment supported by the U.S. since October 2025 than in the previous ...

ViiV Healthcare’s Dovato has been approved for use in the US and EU since 2019, but its sales remain overshadowed by Gilead’s Biktarvy.

South Africa has more than half of all Africans using the world's newest HIV prevention injection. But the real story lies ...

For more than two decades, scientific innovation and international financing have worked together to transform HIV from a ...

Study reveals that 77% of US partners had to adapt their work to Washington’s latest policies, with conditions surrounding ...

Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least ...

People with hearing loss who received a hearing-aid prescription faced a 5.0 percent chance of developing dementia over seven ...

A new research study examining the scale of disruptions to HIV programmes caused by funding cuts from the United States’ ...

A new antiretroviral combination pill that is taken only once a week appears to work as well as daily pills at treating HIV. This is according to interim study findings to be presented next week at ...